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IN VIVO EFFICACY EVALUATION FOR AN ALCOHOL-BASED HAND RUB
(ABHR) AGAINST HUMAN NOROVIRUS SURROGATES
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Purpose: Hand hygiene is a crucial measure for infection control to prevent
transmission of pathogens causing acute infectious gastroenteritis through
contaminated hands. We mainly report here a battery of virucidal efficacy
data through determining human norovirus surrogate-eliminating activity
in vivo for a newly-improved Alcohol-Based Hand Rub (ABHR) and also focus
on testing-methodological aspects from the standpoint of standardization in
Japan.
Methods: A newly-improved ABHR was evaluated according to ASTM E 2011-
13 in vivo. Virucidal assays were also conducted against varieties of strains
including non-enveloped viruses according to the testing methodology of
ASTM E 1052-11 in vitro.
Results: The ABHR demonstrated significant efficacies of greater than 2.30 
0.28 log10 reduction against Feline calicivirus and of 2.48  0.47 log10 reduc-
tion against Murine norovirus as surrogates for human norovirus relative to
baseline viral populations based on the in vivo testing method (p < 0.05)
and met the criteria of Health Canada’s guidance in 2009. A series of efficacy
data against 10 kinds of viruses including Feline calicivirus (more than 4.97
log10 reduction) and Murine norovirus (2.75 log10 reduction) in 15 second
were also given in vitro.
Conclusions: From the study results, it was found the novel ABHR had a po-
tential to pass the efficacy criteria of the guidance of Health Canada.
Furthermore, we presented a possibility to choose a testing method based
on outline of European committee for standardization (CEN) protocol as a
standardized methodology in Japan for in vivo virucidal efficacy evaluation
in the future.PS 2-344
DIFFICULT-TO-TREAT LIFE-THREATENING CMV PNEUMONIA: A CASE
REPORT
Mei-Yu Su a, Wen-Liang Yu a,b, Che-Kim Tan a. aDepartment of Intensive
Care Medicine, Taiwan; bChi-Mei Medical Center, Tainan City, Taiwan
Purpose: Cytomegalovirus (CMV) infection occurs in 0 to 36% of critically ill
patients, mostly between 4 and 12 days after intensive care units (ICU)
admission. Treatment of CMV pneumonia may be difficult. We report a
case of treatment failure of CMV pneumonia.
Case report: A 66-year-old man of nephrotic syndrome, chronic kidney dis-
ease (CKD), diabetes mellitus, adrenal insufficiency with regular control at
our OPD suffered from dysuria with decreased urine output for 3 days. He
was brought to emergency department on September 8, 2014. Laboratory
data shows leukocytosis, creatinine 7.51 mg/dL, and hyperkalemia. Emer-
gent hemodialysis and ceftriaxone were used. He was transferred to the
ward. Regular hemodialysis was used from perm-cath since September 17,
2014. Due to conscious change, brain CT was performed and showed small
deep old infarct. He was admitted to intensive care unit (ICU) on October
12, 2014. He received emergent endotracheal tube insertion with mechani-
cal ventilator use due to sudden onset of dyspnea and respiratory failure.
CXR showed worsening of mixed airspace and interstitial infiltration over
bilateral lungs. Sputum culture showed Pseudomonas aeruginosa. Antibiotic
was shifted to meropenem and tigecycline. Blood and sputum CMV-PCR
showed positive, CMV viral load was low-positive (<137 IU/mL). Aspergillus
Ag index showed 0.15 (negative). Ganciclovir was given on October 15, 2014.
Unstable BP was noted during hemodialysis. CXR showed mixed alveolar and
interstitial infiltration over both lungs, like pneumonia and adult respiratory
distress syndrome. Profound shock then developed requiring high dose vaso-
pressors on October 18, 2014. His condition remained worsening despite
aggressive treatment. Family members requested palliative therapy and
the patient expired on October 24, 2014.
Conclusion: Although the patient did not have cancer, organ transplantation
and AIDS, CKD with poorly responsive pneumonia may suspect CMVpneumonia. Anti-CMV immunoglobulin may be added to ganciclovir therapy
for life-threatening CMV pneumonia, particularly with pathologic diagnosis.PS 2-345
INTRANASAL VACCINATION WITH POLY(I:C) AND CPG AS ADJUVANTS
ENHANCES MUCOSAL AND SYSTEMIC IMMUNE RESPONSES TO AN
ENTEROVIRUS 71 VACCINE
Yu-Li Lin a, Szu-Min Hsieh b, Pei-Yun Cheng a, Hui-Ping Yuan a, Chiao-
Li Chin c, Bor-Luen Chiang c. aDepartment of Medical Research, National
Taiwan University Hospital, Taipei, Taiwan; bInternal Medicine, National
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Purpose: Mucosal vaccines can efficiently induce secretory IgA at mucosal
surfaces, thereby preventing or limiting infection at the site of virus entry.
Since Toll-like receptor (TLR) ligands can act as both the systematic and
mucosal adjuvants. Poly(I:C) is structurally similar to double-stranded
RNA, which is present in some viruses and is a stimulant of TLR3. CpG oligo-
deoxynucleotides (ODNs), resembling bacterial DNA, CpG could induce the
innate immune response through activation of TLR9. We used poly(I:C) and
CpG as adjuvants to study the Enterovirus 71 (EV71) mucosal vaccine.
Methods: Each mouse was intranasal immunized at 0, 3, and 6 weeks. To
evaluate the humoral immune responses, the anti-EV71 IgG and IgA were
assay, and the neutralization test were detected. To evaluate the cellular
immune responses, spleens were harvested to test the splenocyte prolifera-
tion and cytokines production.
Results: Our datas showed that EV71-specific IgA and IgG titers of serum,
nasal wash, BALF, and feces in EV71+poly(I:C)+CpG group was significantly
higher than EV71+poly(I:C) group or EV71+CpG group. Furthermore, there
were more EV71-specific IgA and IgG-producing cells in EV71 adjuvanted
with ploy(I:C)+CpG group. In addition, T-cell proliferative responses, IFN-
a˜, IL-10, and IL-17 secretion were significantly increased when the EV71
was formulated with poly(I:C)+CpG. More importantly, these antibodies
were able to neutralize the infectivity of EV71 (C2 genotype). They also
could cross-neutralized B4 and B5 genotype of EV71 infection.
Figure. Intranasal immunized EV71 with poly(I:C) and CpG to mice can
develop both specific humoral and cellular immune responses to EV71.
Conclusions: Our results indicated that poly(I:C) combined with CpG is an
effective intranasal adjuvant for EV71 vaccine, and IL-17 played an impor-
tant role in mucosal immunity.PS 2-346
COMPLIANCE AMONG CRITICAL CARE NURSES WITH PERFORMING ORAL
CARE PROTOCOLS FOR MECHANICALLY VENTILATED PATIENTS
Hsin-Lan Lin. Department of Nursing, Chi Mei Medical Center, Liouying,
Tainan, Taiwan
Purpose: This study examined the factors related to compliance among crit-
ical care nurses with performing oral care for mechanically ventilated pa-
tients in intensive care units.
Methods: This study was carried out at a regional teaching hospital
comprising a 63-bed adult intensive care unit (ICU) and a 20-bed subacute
respiratory care center (RCC). The protocol for oral care for mechanically
ventilated patients includes oral decontamination with 0.12% chlorhexidine
every eight hours (at the end of the day shift, the evening shift, and the
night shift).
